ArticleThe journal of allergy and clinical immunology. Global2025
Vernal keratoconjunctivitis: The burden of being allergic.
Article in The journal of allergy and clinical immunology. Global, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- Tear Cytokine Signature in Vernal Keratoconjunctivitis: A Chemokine-Remodeling Axis Associated with Disease Severity.International journal of molecular sciences · 2026Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background: Vernal keratoconjunctivitis (VKC) is a chronic inflammatory eye condition predominantly affecting children. Despite its varied clinical manifestations, VKC poses challenges in diagnosis and management because of its multifactorial nature, potentially involving allergic sensitization and comorbidities. Objective: The purpose of this study was to comprehensively assess VKC, focusing on the possible effect of allergic sensitization on the clinical form, severity, and quality of life of pediatric patients with VKC. Methods: In this retrospective study, encompassing 248 children aged 5 to 12 diagnosed with VKC, clinical data, ophthalmologic assessments, and quality-of-life metrics were systematically collected. Patients were divided into sensitized and nonsensitized groups according to allergy investigations. Comprehensive evaluations included clinical history, symptom scoring, Bonini grading for severity, allergen tests, blood examinations, and ophthalmologic examinations. Results: Among the enrolled patients, a prevalence of nonsensitized cases (56%) emerged. Both sensitized and nonsensitized groups displayed similar demographic profiles and clinical forms of VKC. A significantly higher occurrence of rhinitis and asthma was observed in the sensitized group. No significant differences were found in ophthalmologic and hematologic parameters between the 2 groups. Despite this, sensitized patients exhibited a significantly higher impact on quality of life, as indicated by QUICK questionnaire scores. Conclusion: The study underscores the importance of comprehensive allergy assessments during VKC diagnosis, suggesting potential associations between sensitization and atopic comorbidities impacting patients' quality of life. Future investigations into environmental factors, specific allergens, and treatment response are pivotal for a holistic understanding of VKC's implications for pediatric patients' well-being.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.